Search results for " uterine cancer."

showing 3 items of 3 documents

Progestin-releasing intrauterine device insertion plus palliative radiotherapy in frail, elderly uterine cancer patients unfit for radical treatment.

2016

The present study investigated the combination of levonorgestrel-releasing intrauterine device (LNG-IUD) insertion and palliative radiotherapy (RT) as a potential approach for treating frail, elderly endometrial cancer (EC) patients considered unfit for curative oncological treatments. The inclusion criteria were an age of ≥65 years, pathological confirmation of a uterine neoplasm, a Charlson comorbidity index (CCI) value of ≥4 and the presence of vaginal bleeding. Patients underwent intrauterine insertion of an LNG-IUD, and thereafter, received a total dose of 30 Gy at 3 Gy per fraction, over 10 days. The clinical target volume (CTV) was defined as the uterus and disease-involved tissues i…

Cancer Researchmedicine.medical_specialtymedicine.drug_classUterusIntrauterine deviceelderlyuterine cancer03 medical and health sciences0302 clinical medicineUterine cancermedicineVaginal bleedingUterine NeoplasmSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAprogestin-releasing intrauterine device030219 obstetrics & reproductive medicinebusiness.industryEndometrial cancerCancerArticlesmedicine.diseaseSurgeryElderly; Palliative radiotherapy; Progestin-releasing intrauterine device; Uterine cancer; Oncology; Cancer Researchmedicine.anatomical_structureOncology030220 oncology & carcinogenesispalliative radiotherapymedicine.symptombusinessProgestinOncology letters
researchProduct

Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives

2017

Carcinosarcomas (CS) in gynecology are very infrequent and represent only 2–5% of uterine cancers. Despite surgical cytoreduction and subsequent chemotherapy being the primary treatment for uterine CS, the overall five-year survival rate is 30 ± 9% and recurrence is extremely common (50–80%). Due to the poor prognosis of CS, new strategies have been developed in the last few decades, targeting known dysfunctional molecular pathways for immunotherapy. In this paper, we aimed to gather the available evidence on the latest therapies for the treatment of CS. We performed a systematic review using the terms “uterine carcinosarcoma”, “uterine Malignant Mixed Müllerian Tumors”, “target therapies”,…

0301 basic medicineOncologyPathologyAngiogenesisCarcinosarcomas epigenetics genetics immunotherapy uterine cancer.medicine.medical_treatmentReviewEpigenesis Geneticlcsh:Chemistry0302 clinical medicineCarcinosarcomaAntibodies BispecificCarcinosarcomas Epigenetics Genetics Immunotherapy Uterine cancerMedicinegeneticsMolecular Targeted Therapylcsh:QH301-705.5Human Epidermal Growth Factor Receptor 2SpectroscopyNeovascularization PathologicGeneral MedicineEpithelial Cell Adhesion MoleculePrognosisComputer Science ApplicationsErbB ReceptorsSurvival Rate030220 oncology & carcinogenesisUterine NeoplasmsFemaleImmunotherapymedicine.medical_specialtyPoor prognosisMixed Tumor MullerianCatalysisuterine cancerInorganic Chemistry03 medical and health sciencesCancer stem cellInternal medicineBiomarkers TumorHumansTarget therapyPhysical and Theoretical ChemistrycarcinosarcomasMolecular BiologySurvival rateChemotherapyepigeneticsbusiness.industryOrganic ChemistryImmunotherapy030104 developmental biologylcsh:Biology (General)lcsh:QD1-999businessInternational Journal of Molecular Sciences
researchProduct

Characteristics and patterns of care of endometrial cancer before and during COVID-19 pandemic

2021

Objective Coronavirus disease 2019 (COVID-19) outbreak has correlated with the disruption of screening activities and diagnostic assessments. Endometrial cancer (EC) is one of the most common gynecological malignancies and it is often detected at an early stage, because it frequently produces symptoms. Here, we aim to investigate the impact of COVID-19 outbreak on patterns of presentation and treatment of EC patients. Methods This is a retrospective study involving 54 centers in Italy. We evaluated patterns of presentation and treatment of EC patients before (period 1: March 1, 2019 to February 29, 2020) and during (period 2: April 1, 2020 to March 31, 2021) the COVID-19 outbreak. Results M…

medicine.medical_specialtyendometrial neoplasmsCoronavirus disease 2019 (COVID-19)Endometrial Cancer; COVID-19; Uterine cancer; SARS-CoV-2covid-19; endometrial cancer; sars-cov-2; uterine cancer; female; humans; pandemics; retrospective studies; sars-cov-2; covid-19; endometrial neoplasmspandemicsEndometrial CancerNOCOVID-19; Endometrial Cancer; SARS-CoV-2; Uterine cancerRetrospective StudiePandemicmedicineUterine cancerhumansPatterns of carePandemicObstetricsbusiness.industrySARS-CoV-2Endometrial cancerObstetrics and GynecologyCOVID-19General Medicinemedicine.diseaseEndometrial Neoplasmsretrospective studiesSettore MED/40 - GINECOLOGIA E OSTETRICIAfemaleOncologyOriginal ArticleFemalebusinessHuman
researchProduct